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Immunosuppressive activity enhances central
carbon metabolism and bioenergetics in
myeloid-derived suppressor cells in vitro models
Ines Hammami1, Jingkui Chen1, Frederic Murschel1, Vincenzo Bronte2, Gregory De Crescenzo1
and Mario Jolicoeur1*
Abstract
Background: The tumor microenvironment contains a vast array of pro- and anti-inflammatory cytokines that alter
myelopoiesis and lead to the maturation of immunosuppressive cells known as myeloid-derived suppressor cells
(MDSCs). Incubating bone marrow (BM) precursors with a combination of granulocyte-macrophage colony-
stimulating factor (GM-CSF) and interleukin-6 (IL-6) generated a tumor-infiltrating MDSC-like population that
impaired anti-tumor specific T-cell functions. This in vitro experimental approach was used to simulate MDSC
maturation, and the cellular metabolic response was then monitored. A complementary experimental model that
inhibited L-arginine (L-Arg) metabolizing enzymes in MSC-1 cells, an immortalized cell line derived from primary
MDSCs, was used to study the metabolic events related to immunosuppression.
Results: Exposure of BM cells to GM-CSF and IL-6 activated, within 24 h, L-Arg metabolizing enzymes which are
responsible for the MDSCs immunosuppressive potential. This was accompanied by an increased uptake of L-
glutamine (L-Gln) and glucose, the latter being metabolized by anaerobic glycolysis. The up-regulation of nutrient
uptake lead to the accumulation of TCA cycle intermediates and lactate as well as the endogenous synthesis of L-
Arg and the production of energy-rich nucleotides. Moreover, inhibition of L-Arg metabolism in MSC-1 cells down-
regulated central carbon metabolism activity, including glycolysis, glutaminolysis and TCA cycle activity, and led to
a deterioration of cell bioenergetic status. The simultaneous increase of cell specific concentrations of ATP and a
decrease in ATP-to-ADP ratio in BM-derived MDSCs suggested cells were metabolically active during maturation.
Moreover, AMP-activated protein kinase (AMPK) was activated during MDSC maturation in GM-CSF and IL-6–treated
cultures, as revealed by the continuous increase of AMP-to-ATP ratios and the phosphorylation of AMPK. Likewise,
AMPK activity was decreased in MSC-1 cells when L-Arg metabolizing enzymes were inhibited. Finally, inhibition of
AMPK activity by the specific inhibitor Compound C (Comp-C) resulted in the inhibition of L-Arg metabolizing
enzyme activity and abolished MDSCs immunosuppressive activity.
Conclusions: We anticipate that the inhibition of AMPK and the control of metabolic fluxes may be considered as
a novel therapeutic target for the recovery of the immunosurveillance process in cancer-bearing hosts.
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Tumor growth and progression are critically controlled
by alterations in the microenvironment, often caused by
aberrant expression of tumor-derived soluble factors
(TDSFs) [1]. In addition to stimulating tumor cell prolif-
eration, stromal activation and angiogenesis, TDSFs pro-
mote the maturation/recruitment of myeloid-derived
suppressor cells (MDSCs) that inhibit the tumor-specific
functions of CD8+ and CD4+ T lymphocytes [2]. MDSCs
have been characterized in tumor-bearing mice by the
expression of the surface markers CD11b and Gr-1 [3].
Their immunosuppressive functions depend on two
enzymes: i) inducible nitric oxide synthase (iNOS) that
converts L-arginine (L-Arg) to nitric oxide (NO) and L-
citrulline, and ii) arginase 1 (ARG1) that metabolizes L-
Arg into urea and L-ornithine. A decreased availability
of L-Arg combined with the accumulation of NO deriva-
tives (NO2
- , NO3
- , N2O3) trigger the inhibition of T-cell
function and proliferation, and induce cell death [3].
Despite considerable progress in understanding MDSC
maturation both in vivo and in vitro, mechanisms of im-
munosuppression at the metabolic level are still unclear.
Specific immune functions, including antigen processing
and presentation, cytokinesis and activation, are known
to be energetically-costly [4]. Moreover, immune cells,
such as lymphocytes and macrophages, modulate their
metabolism and respiration to fulfill their energy
requirements. The energy metabolism of immune ef-
fector cells was thus considered a potential target for im-
munotherapy. Indeed, drugs that affect cell bioenergetics
can reduce ATP production, for the treatment of psoria-
sis, rheumatoid arthritis, and cardiac arrhythmia. These
drugs act either by inhibiting reactions related to sub-
strate oxidation or by increasing proton permeability
through the mitochondria, in turn resulting in the un-
coupling of oxidative phosphorylation [4].
Therefore, to better understand the nutritional and en-
ergy requirements of MDSCs, two complementary ex-
perimental models were used. The first consisted of
in vitro maturation of bone marrow (BM)-derived
MDSCs using a combination of granulocyte-macrophage
colony-stimulating factor (GM-CSF) and interleukin
(IL)-6, as previously reported [5], which generated a
CD11b+/Gr-1low population, the most tolerogenic and im-
munosuppressive sub-population among CD11b+/Gr-1+
cells [6]. This cell population expresses iNOS and ARG1,
and has a similar genetic signature to tumor-infiltrating
MDSCs [5]. To discern whether the metabolic changes
that occur during maturation are related to the direct
effects of GM-CSF and IL-6 on metabolic pathways and
nutrient transporters, or are associated with the activation
of iNOS and ARG1, we used a second model that inhib-
ited iNOS and ARG1 activity in MSC-1 cells, an immorta-
lized cell line derived from mouse MDSCs. Beingphenotypically similar to primary MDSCs, the MSC-1 cell
line represents a relevant model system. MSC-1 cells con-
stitutively expressed iNOS and ARG1 and inhibited
antigen-specific proliferation and functions of cytotoxic T-
lymphocytes without any additional treatment with spe-
cific cytokines or endotoxins, as previously demonstrated
[7,8]. Comparing the results, we further confirmed the
MSC-1 cell line as a model system.
iNOS and ARG1 activities were respectively inhibited
by N-[3-(aminomethyl)-benzyl]-acetamidine (1400 W)
and [(S)-(2-boronoethyl)-L-cysteine] (BEC). 1400 W was
selected as it is a tight-binding and highly selective in-
hibitor of iNOS exhibiting the highest potency of
reported iNOS inhibitors [9]. BEC is a potent slow-
binding competitive and selective inhibitor of ARG1
[10]. Both 1400 W and BEC inhibitors act directly on
enzymatic activity, without affecting enzyme mRNA or
protein levels [9,10].
Results of the present study suggest MDSC maturation
and immunosuppressive potential are accompanied by
an increase in the central carbon metabolism activity
level and bioenergetic status. This study also emphasizes
the key role of AMPK in the maintenance of MDSCs
immunosuppressive activity.
Results
Immunosuppressive activity of BM-derived MDSCs and
MSC-1 cells
The enzymatic activities of iNOS and ARG1 were ex-
tremely low in BM cell culture, as revealed by a constant
concentration of nitrate and nitrite in the supernatant
(62.86 ± 4.25 μM) and constant ARG1 activity at
124.93 ± 3.48 nU/cell throughout the culture (Figure 1A,
B). Thus, although CD11b+/Gr-1+ cells can be detected
at sizeable number in BM of healthy mice [3], BM cells
have no immunosuppressive potential (Figure 1C, D). In
fact, a cytotoxicity assay showed that BM cells did not
affect Jurkat cell growth or viability (Figure 1C, D). In
contrast, treating BM cells with GM-CSF and IL-6
resulted in a marked increase of ARG1 and iNOS activ-
ity after 16 h and 24 h, respectively. Nitrate and nitrite
continuously accumulated at a rate of 6.64 ± 0.09 fmol/
cell/h while ARG1 activity shifted from 122.17 ± 0.65
nU/cell at inoculation to 174.79 ± 3.58 nU/cell at 16 h,
and continuously increased until a quasi-stable level of
304.30 ± 4.11 nU/cell was attained at 72 h. The accumu-
lation of nitrate and nitrite suggested that L-Arg was
permanently present in the supernatant, otherwise iNOS
and ARG1 activities would be down-regulated and a loss
of BM-derived MDSC immunosuppressive activity
would be observed. The ability of BM-derived MDSCs
to inhibit Jurkat cell growth and decrease their viability
was detected after 48 and 72 h of treatment, respectively
(Figure 1C, D). This delay was likely due to an increase
Figure 1 Immunosuppressive activity of BM-derived MDSCs and MSC-1 cells. BM cells were extracted from 6 to 8-week-old C57BL/6 mice
and cultured for 4 days in the presence of GM-CSF and IL-6 (40 ng/ml each, except for the control cultures). MSC-1 cells were cultured for 48 h in
the presence of 100 μM of 1400 W and 5 μM of BEC (except for control cultures). (A) Nitrite and nitrate concentration based on the Griess
reaction. (B) ARG1 activity: one unit (U) of ARG1 activity is defined as the enzyme activity that catalyses the production of 1 μmol urea/min. Filled
and empty symbols (■, □) correspond to BM cells and BM-derived MDSC cultures, respectively. Filled and empty symbols (▲, △) correspond to
MSC-1 cells and 1400 W and BEC-treated MSC-1 cells, respectively. The same nomenclature is used for all figures unless specified. (C, D) Ratios
(referenced to the control culture) of Jurkat cell density and viability, respectively. Jurkat cells were cultured for 24 h in the presence of untreated
BM cells (Black), BM cells exposed to GM-CSF and IL-6 for 24, 48, 72 or 96 h (hatched) and cytokines (Grey). (E, F) Ratios (referenced to the control
culture) of Jurkat cell density and viability, respectively. Jurkat cells were inoculated in the presence of MSC-1 cells (Black) or MSC-1 cells pre-
cultured for 12 h in the presence of 1400 W (100 μM) and BEC (5 μM) (White). Ratios are based on the cell density and viability of the control
culture, which consists of Jurkat cells inoculated in inserts (500 μl at 0.2 × 106 cells/ml) placed in wells containing 500 μl of complemented culture
medium. The same control culture is considered for subsequent cytotoxicity tests.
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cell suspension, since BM cells were not synchronized
prior to GM-CSF and IL-6 addition. More specifically,
after 96 h of treatment, BM-derived MDSCs decreased
Jurkat cell density and viability by 46.6 ± 1.07 and
26.47 ± 0.89%, respectively. Culturing Jurkat cells in the
presence of GM-CSF and IL-6 did not affect cell growthor viability (Figure 1C, D), suggesting that the effects
observed in the treated-BM and Jurkat mixed cell cul-
ture were caused by the maturation of BM-derived
MDSCs, and not to cytokine-related cytotoxic effects.
It is important to note that the phenotype and gen-
omic profile of GM-CSF and IL-6-treated BM cells were
not re-verified herein, since we used the same protocol
Hammami et al. BMC Cell Biology 2012, 13:18 Page 4 of 15
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age, sex, euthanasia protocol, BM cell extraction, and
chemical products for cell extraction and culture [5]. As
discussed, the L-Arg metabolizing enzymes, iNOS and
ARG1, were both activated following GM-CSF and IL-6
exposure, and the resulting cells were immunosuppres-
sive. This suggests that cytokine-treated BM cells behave
as MDSCs at the immunosuppression level.
However, culturing MSC-1 cells in the presence of
1400 W and BEC triggered the rapid inhibition of iNOS
activity, since the concentration of nitrate and nitrite, used
as a marker of iNOS activity, remained constant at
50.03 ± 4.57 μM, whereas nitrate and nitrite accumulated
at a rate of 2.33± 0.09 μM/h in the control culture
(Figure 1A). The high concentrations of nitrate and nitrite
in the control culture did not affect MSC-1 cell viability,
which was maintained at higher than 97% throughout the
48 h culture (data not shown). The inhibition of ARG1 ac-
tivity occurred at different rates (Figure 1B). ARG1 activity
was decreased by 50% during the first 12 h of treatment,
and then decreased from 45.78 ± 9.78 nU/cell/h at 12 h, to
9.42± 0.64 nU/cell/h at 36 h, and remained relatively
stable until the end of the culture (48 h).
High concentrations of inhibitors (100 μM for 1400 W
and 5 μM for BEC) in comparison with the 1400 W half
maximal effective concentration (EC50) of 0.8 ± 0.3 μM
[9] and the BEC dissociation constant (Ki) of 0.5 ± 0.1 μM
[11]), were used to achieve maximum inhibition of iNOS
and ARG1 activity in newly divided MSC-1 cells. These
concentrations did not induce loss of cell viability (data
not shown) or growth inhibition, and similar specific
growth rates were observed for the control culture
(0.047± 0.001 per h) and cells treated with 1400 W and
BEC (0.046± 0.003 per h). Moreover, the use of high con-
centrations of 1400 W and BEC are commonly reported
in the literature without any noticeable cytotoxic effect
on several different cell types [12-15].
The cytotoxicity assay showed that co-culturing Jurkat
and MSC-1 cells pre-treated with 1400 W and BEC
reduced the immunosuppressive potential of MSC-1
cells. Indeed, Jurkat cell density (Figure 1E) and viability
(Figure 1F) were similar to those measured in the con-
trol culture (Jurkat cells only). In contrast, in the pres-
ence of untreated MSC-1 cells, Jurkat cell density and
viability after 32 h were decreased by 37.08 ± 5.03% and
25.25 ± 2.32%, respectively, when compared to the con-
trol culture (p< 0.05). Exposure of Jurkat cells to
1400 W and BEC in the absence of MSC-1 cells did not
affect their growth or viability (data not shown).
Immunosuppression activity affects the nutritional profile
of BM-derived MDSCs and MSC-1 cells
BM-derived MDSCs exhibited a low specific growth rate
of 0.13 ± 0.02 per d from 32 h, whereas no cell growthwas detected in the untreated BM cell culture (control
culture) although cells stayed viable throughout the cul-
ture. BM-derived MDSCs consumed glucose at a high
rate of 0.243 ± 0.008 pmol/cell/h from 24 h, whereas the
control culture scarcely consumed glucose during the
first 72 h and then at a rate of 0.278 ± 0.013 pmol/cell/h
(Figure 2A). The increase of glucose uptake in the BM-
derived MDSC culture was accompanied by the accumu-
lation of glycolysis intermediates from 32 h. The cell
specific concentration of glucose-6-phosphate (G-6-P)
and fructose-6-phosphate (F-6-P) increased at rates of
5.173 ± 0.084 and 3.573 ± 0.005 × 10-3 fmol/cell/h, re-
spectively (Figure 2B), showing that G-6-P is mostly pro-
cessed through glycolysis and lower quantities enter the
pentose phosphate pathway (PPP). The increase of cell
specific concentrations of glycolysis intermediates in the
BM cell culture, coincided with the increased glucose
consumption rate (72 h) (Figure 2B, C). Moreover, the
enhanced glucose uptake was accompanied by decreased
cell respiration. The specific oxygen consumption rate
decreased from 103.42 ± 6.14 fmol/cell/h at 24 h to
41.88 ± 3.62 fmol/cell/h at 96 h (data not shown). The
lactate-to-glucose yield, in the GM-CSF and IL-6 -
treated BM cell culture, was relatively stable at
0.61 ± 0.02 for the first 24 h and then rapidly increased
to 1.39 ± 0.04 at 32 h and reached values higher than
2.00 after 80 h (Figure 2D), suggesting that another
source of carbon contributed to the accumulation of lac-
tate. Conversely, the lactate-to-glucose yield of the BM
cell culture was almost stable at 0.95 ± 0.02 (Figure 2D).
The activation of iNOS and ARG1, within the first
24 h, was followed by changes in glycolytic intermediates
and cell respiration levels at 32 h. We then investigated
whether iNOS and ARG1 activation has a direct effect on
the metabolic shifts. The characterization of MSC-1 and
1400 W and BEC-inhibited MSC-1 cell nutritional pro-
files led to similar interpretations. The inhibition of iNOS
and ARG1 activities resulted in the decrease of specific
glucose consumption rate from 0.292 ± 0.018 pmol/cell/h
(control culture) to 0.153 ± 0.008 pmol/cell/h. This was
accompanied by an increase in cell specific oxygen con-
sumption rate from 0.066 ± 0.005 pmol/cell/h (control
culture) to 0.108 ± 0.001 pmol/cell/h. The ratio of the
consumption rates of oxygen-to-glucose increased from
0.23 ± 0.03 in the control culture to 0.72 ± 0.5 in the
1400 W and BEC-treated cultures. In agreement with the
lower glucose uptake rate, lactate production rate was
also reduced from 0.511 ± 0.028 pmol/cell/h (control cul-
ture) to 0.292 ± 0.021 pmol/cell/h when iNOS and ARG1
were inhibited. However, the lactate-to-glucose yield
slightly increased from 1.78 ± 0.18 in the control culture
to 1.92 ± 0.24 in the 1400 W and BEC-treated culture.
Furthermore, BM-derived MDSCs consumed L-Gln at a
higher rate (0.040 ± 0.002 pmol/cell/h) than that
Figure 2 GM-CSF and IL-6 modulate BM-derived MDSC glucose metabolism. (A) Glucose concentration in the supernatant. (B) Cell specific
concentrations in G-6-P (squares) and F-6-P (triangles). (C) Cell specific PEP concentration. (D) Lactate-to-glucose yield. BM cells and BM-derived
MDSCs were extracted using cold methanol and organic acids were analyzed using a UPLC-MS/MS system.
Hammami et al. BMC Cell Biology 2012, 13:18 Page 5 of 15
http://www.biomedcentral.com/1471-2121/13/18observed in the control culture (0.021 ± 0.005 pmol/cell/
h) (Figure 3A). This was confirmed by a decrease in the
L-Gln consumption rate from 0.086 ± 0.004 pmol/cell/h
(control culture) to 0.052 ± 0.001 pmol/cell/h in the pres-
ence of 1400 W and BEC. Interestingly, only slight differ-
ences in nutrient consumption and metabolite
production rates were observed between MSC-1 cells
and BM-derived MDSCs cultures, and similar results
have been observed for both models in the current study.
The stimulation of glycolysis and glutaminolysis in BM-
derived MDSC cultures resulted in an increase in the cell
content of TCA cycle intermediates. Particularly, α-
ketoglutarate (α-KG), which can be derived from isocitrate
or L-Gln, accumulated at a rate of 5.873± 0.005× 10-3
fmol/cell/h (Figure 3B). Similarly, the cell specific concen-
tration of fumarate, a by-product of the conversion of
argininosuccinate into L-Arg, increased at a rate of
20.378± 0.005× 10-3 fmol/cell/h after 24 h (Figure 3C),
strongly suggesting that maturation of BM cells to MDSCs
was accompanied by the activation of the L-Arg recycling
pathways. Moreover, measurement of the cell specific con-
centrations of both sources of pyruvate, malate, which is
derived from fumarate, and phosphoenolpyruvate (PEP),
indicated that malate was 5-fold more concentrated than
PEP (Figures 2C, 3D). Consistent with the down-
regulation of the net uptake rates of major nutrients (glu-
cose and L-Gln), inhibiting iNOS and ARG1 activitiesresulted in a decrease of the specific cell concentrations of
TCA cycle substrates, particularly α-ketoglutarate, fumar-
ate and malate (Figure 3B, C, D).
Immunosuppression-related bioenergetics
Consistent with the stimulation of central carbon metab-
olism during the maturation process, the BM-derived
MDSC bioenergetic state was up-regulated. The intracel-
lular pools of purines (GTP+ATP+ADP+AMP), which
represent energy-related nucleotides, and pyrimidines
(CTP+UTP+UDPGNAc), which are involved in various
anabolic reactions and growth-related metabolic pro-
cesses [16,17], increased at the respective rates of
0.030 ± 0.007 and 0.014 ± 0.002 fmol/cell/h after 24 h of
treatment (Figure 4A). The BM-derived MDSC energetic
pool mainly constituted of purines (60 to 70%), an
expected result considering the low specific growth rate.
Conversely, the purine pool was relatively stable at
0.46 ± 0.03 fmol/cell/h in the control culture, and pyr-
imidine levels showed a decrease due to cell quiescence
(Figure 4A). In particular, ATP was accumulated at a
rate of 26.398 ± 2.789 × 10-3 fmol/cell/h from 24 h. The
enhanced activity of the TCA cycle may thus have indir-
ectly contributed to the production of ATP, since glyco-
lytic metabolism has a low energy yield (Figure 4B).
Furthermore, the cell specific concentration of NADPH
increased at a rate of 1.68 ± 0.04 × 10-3 fmol/cell/h
Figure 3 Regulation of glutaminolysis and TCA cycle during immunosuppression. (A) L-Gln concentration in supernatant. (B, C, D) Specific
cell concentrations of α-KG, fumarate and malate, respectively.
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accumulation shifted rapidly to 9.72 ± 0.02 × 10-3 fmol/
cell/h between 64 and 80 h. In addition to the role of
the oxidative phase of PPP in NADPH production, mal-
ate dehydrogenase and isocitrate dehydrogenase produce
considerable amounts of NADPH along with pyruvate
and α-ketoglutarate, respectively. Thus, ATP and
NADPH production rates were higher than the demand
for maturation and the resulting immunosuppressive
machinery. The cell specific NADPH concentration
slightly decreased from 0.382 ± 0.031 fmol/cell at 80 h to
0.0341 ± 0.016 fmol/cell at the end of the culture (96 h),
suggesting either higher demands from NADPH-
requiring processes or the down-regulation of NADPH
production.
The inhibition of iNOS and ARG1 activities decreased
the cell specific ATP concentration from 5.16± 0.20 fmol/
cell (at inoculation) to 2.49± 0.25 fmol/cell after 24 h, and
then increased at a rate of 0.046 ± 0.007 fmol/cell/h until
the end of the culture (96 h) (Figure 4B). However, in the
control culture, ATP continuously accumulated at a rate
of 0.033 ± 0.002 fmol/cell/h to a maximal value of
7.33± 0.12 fmol/cell/h at 48 h. Similarly, MSC-1 cell spe-
cific NADPH concentrations were stable at 1.60± 0.03
fmol/cell in the presence of 1400 W and BEC, whereas it
progressively accumulated at a rate of 0.034 ± 0.009 fmol/
cell/h in the control culture (Figure 4C).An exhaustive study of nucleotide-derived biomarkers
showed that cell metabolic activity increased as MDSC
maturation progressed. Treating BM cells with GM-CSF
and IL-6 increased the NTP ratio, defined as ([ATP] +
[GTP])/([UTP] + [CTP]) the ratio of energetic nucleotides
to anabolism-related nucleotides [17], from 3.14± 0.07
(during the first 24 h) to 5.36± 0.06 at the end of the
culture (96 h) (Figure 4D). An increase in the NTP ratio
normally indicates the deterioration of cell metabolic ac-
tivity if the cell growth process was active. In this case,
the rates of ATP (Figure 4B) and GTP (data not shown)
accumulation were higher than those of CTP and UTP
(data not shown), indicating that BM-derived MDSCs
were catabolically active. Nevertheless, the NTP ratio of
the control culture increased rapidly after cell inocula-
tion, and reached a plateau (5.34 ± 0.014) at 32 h. This
increase was mostly caused by a decrease in pyrimidines
in the cell pool.
Although the cell specific ATP concentration increased
during culture (Figure 4B), ATP was continuously
depleted from the intracellular pool during maturation as
the ATP-to-ADP ratio, a marker of respiration and energy
consumption, decreased [18] (Figure 4E). Indeed, the
ATP-to-ADP ratio in the BM-derived MDSC culture was
2 to 3 times lower than that of the control culture, and
decreased at a specific rate of 0.058 ± 0.002 per h. How-
ever, the ATP-to-ADP ratio in iNOS and ARG1-inhibited
Figure 4 Bioenergetic status of BM-derived MDSCs. (A) Specific cell concentration in purines (GTP+ATP +ADP+AMP, squares) and
pyrimidines (CTP +UTP+UDPGNAc, triangles). (B) Specific cell concentration of ATP. (C) Specific cell concentration of NADPH. Nucleotide-derived
behavioral markers: (D) NTP ratio (ATP+GTP)/(UTP+ CTP) in BM cells and BM-derived MDSC cultures. (E) ATP-to-ADP ratio. (F) AMP-to-ATP ratio.
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oculation) to 1.22 ± 0.31 after 24 h, with a slight increase
thereafter (Figure 4E). Conversely, this ratio continuously
increased from 3.46 ± 0.19 (at inoculation) to a plateau
value of 4.82 ± 0.38 at 30 h in the control culture. This
decrease was probably caused by anabolic-related energy
consumption, since inhibitors did not induce any re-
markable effects on cell growth or viability.
However, the AMP-to-ATP ratio, which is considered
a marker of glycolysis stimulation and a regulator of
AMPK activity [19], shifted after 24 h and was consid-
erably higher than in the control culture, indicating
sustained ATP production (Figure 4F). Moreover, the
AMP-to-ATP ratio in the iNOS and ARG1-inhibited
MSC-1 cell culture was 2 to 5-fold lower than that of the
control culture, suggesting AMPK activity is probablyregulated by the cellular immunosuppressive potential
(Figure 4F).
Role of AMPK in BM-derived MDSC maturation
The increase of AMP-to-ATP ratios observed during the
MDSC maturation process suggested that AMPK is
implicated in the regulation of cells bioenergetics. This
hypothesis was confirmed by western blot analysis,
where the expression level of phosphorylated AMPK (p-
AMPK) increased in the presence of GM-CSF and IL-6
(Figure 5A), whereas p-AMPK was not detectable in the
BM cell culture (Figure 5B). Moreover, AMPK is critical
for prostaglandin E2 (PGE2)-induced differentiation of
BM cells to endothelial progenitor cells [20,21], and
PGE2-induced differentiation of CD11b+/Gr-1+ MDSCs
in tumor-bearing animals [22]. We have then verified
Figure 5 Implication of AMPK in the maturation of BM cells to MDSCs. (A) p-AMPK to AMPK ratio in BM-derived MDSCs as analyzed by
densitometry analysis of western blot bands. (B) p-AMPK and AMPK after 96 h in BM cells, BM-derived MDSCs, Comp-C pre-treated BM cells
(5 μM, 15 min) cultured in the presence of GM-CSF and IL-6 (40 ng/ml). (C) Nitrate and nitrite concentrations in supernatants. Filled and empty
squares (■, □) correspond to BM cells and BM-derived MDSC cultures, respectively. Empty circles (○) represent Comp-C pre-treated BM cells
cultured in the presence of GM-CSF and IL-6. (D) ARG1 activity. Untreated BM cells (Black), BM cells exposed to GM-CSF and IL-6 for 24, 48, 72 or
96 h (hatched) and Comp-C pre-treated BM cells rinsed with sterile PBS and then cultured in the presence of GM-CSF and IL-6 (Grey). The same
nomenclature is used for Figure 5E and F. (E, F) Ratios (referenced to the control culture) of Jurkat cell density and viability respectively.
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of BM-derived MDSCs immunosuppressive potential.
Treating BM cells with 5 μM of Comp-C for 15 min was
sufficient to inhibit the phosphorylation of AMPKα1/2
at Thr172 throughout the 96 h culture (Figure 5B), with-
out affecting AMPK expression levels or cell growth and
viability (data not shown). As expected, the inhibition of
AMPK activity by Comp-C resulted in a lower glucose
uptake rate of 0.157 ± 0.011 pmol/cell/h, when compared
to the GM-CSF and IL-6–treated BM cell culture
(0.293 ± 0.007 pmol/cell/h). Pre-treatment of BM cellswith Comp-C prior to cytokine addition maintained the
lactate-to-glucose ratio at a lower value (0.88 ± 0.04)
compared with the high lactate-to-glucose yield
(1.82 ± 0.03) observed in the BM-derived MDSC culture.
This suggests that AMPK-inhibited BM cells cultured
in the presence of GM-CSF and IL-6 favored energy
production rather than lactate accumulation, or that
the L-Gln-derived lactate production rate had decreased.
However, L-Gln did not compensate for the decrease
of glucose-derived carbon, since the L-Gln uptake
rate slightly decreased in the presence of Comp-C
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control culture (0.023 ± 0.004 pmol/cell/h). In addition to
lower nutrient uptake rates, the inhibition of AMPK ac-
tivity was accompanied by inhibition of iNOS and ARG1
activity. The concentration of nitrate and nitrite, markers
of iNOS activity, remained constant at 63.80 ± 3.41 μM
in AMPK-inhibited BM cells cultured with GM-CSF and
IL-6, whereas BM-derived MDSCs produced nitrate and
nitrite at a rate of 8.13 ± 0.13 fmol/cell/h (Figure 5C).
Similarly, GM-CSF and IL-6 failed to activate ARG1
when AMPK was inhibited since ARG1 activity remained
constantly low at (124.63± 2.64 nU/cell) similar to the
control culture (Figure 5D). ARG1 activity increased at
different rates and reached high values (314.30± 2.63 nU/
cell) in the BM-derived MDSC culture. The inhibition of
iNOS and ARG1 activities in the AMPK-inhibited BM
cells abolished the immunosuppressive potential since
cells failed to inhibit the growth and viability of Jurkat
cells. However, BM-derived MDSCs reduced Jurkat cell
density and viability by 49.9 ± 3.71 and 27.1 ± 1.1%, re-
spectively (Figure 5E, F).Discussion
Co-induction of ARG1 and iNOS by bacterial lipopoly-
saccharide in macrophages modulates central carbon me-
tabolism and respiration [23,24], and the cell bioenergetic
state. Since tumor-infiltrating MDSCs have the highest
immunosuppressive potential among different MDSC
sub-populations [6], we simulated the maturation of BM
precursors to MDSCs using a combination of GM-CSF
and IL-6, in vitro. Complementary to work conducted by
Marigo et al., where BM-derived MDSCs were harvested
after 96 h of treatment [5], we continuously monitored
the progression of MDSC maturation every 8 h. We also
characterized MSC-1 cells nutritional profile and ener-
getic states when iNOS and ARG1 activities were inhib-
ited, to analyze the immunosuppression-related energy
demand. A greater understanding of immunosuppression
at the metabolic level may be significant for the identifica-
tion of new immunotherapy targets.
Exposure of BM cells to GM-CSF and IL-6 induced a
continuous up-regulation of iNOS and ARG1 activities
after 24 and 16 h, respectively (Figure 1A, 1B). The delayed
effects can be attributed to cytokine internalization and to
activation of the CCAAT-enhancer-binding protein (C/
EBP)β transcription factor [5] and other signaling pathways
(JAK/STAT3, MAPK and PI3-K) that were shown to regu-
late the expression and activation of L-Arg metabolizing
enzymes [25]. However, BM-derived MDSCs only exhib-
ited their immunosuppressive potential after 48 to 72 h ex-
posure to cytokines, which corresponded to the initiation
of Jurkat cell growth inhibition and loss of viability, re-
spectively (Figure 1C, D). The immunosuppressive activityof BM-derived MDSCs was not observed until sufficient L-
Arg was sufficiently removed from the culture medium
allowing NO derivatives to accumulate.
The activation of iNOS and ARG1 was accompanied
by the up-regulation of glucose uptake (Figure 2A) and
glycolysis, as shown by the AMP-to-ATP ratio, which
was up to 5-fold higher than in the control culture
(Figure 4F), and by the accumulation of G-6-P and F-6-
P (Figure 2B). This accumulation may suggest that cells
continue producing these intermediates without con-
suming them, a behavior previously associated with the
initiation of cell death [17]. However, cells remained vi-
able and grew throughout the culture. L-Arg and lactate
were continuously produced, suggesting that cells con-
sumed these intermediates to support both the catabolic
processes and the sparse synthesis of anabolism-related
macromolecules. Thus, the accumulation is caused by a
higher rate of production compared with consumption.
The cell specific concentration of F-6-P, which was ap-
proximately 60% to 70% that of G-6-P, suggests that glu-
cose is mainly processed by glycolysis (Figure 2B). This
may be a consequence of the low specific growth rate
exhibited by BM-derived MDSCs, which may have lim-
ited fluxes of the non-oxidative reactions of the PPP.
These results are in agreement with previous studies by
Ando et al., where IL-6 enhanced the expression of the
glycolytic enzymes hexokinase 2 and 6-phosphofructo-2
-kinase/fructose-2,6-biphosphatase-3 in mouse embry-
onic fibroblasts via the IL-6/STAT3 pathway [26]. Simi-
larly, GM-CSF promoted rapid glucose transport in
Xenopus oocytes via the PI3-K pathway [27]. L-Gln up-
take was also increased in the presence of GM-CSF and
IL-6 (Figure 3A). In addition to the possible direct effect
of cytokines on nutrient uptake, the enzymatic activities
of iNOS and ARG1 indirectly regulated glucose and L-
Gln consumption since the inhibition of iNOS and
ARG1 activities in MSC-1 cells down-regulated glucose
and L-Gln uptake. Therefore, the abolition of MSC-1
cells immunosuppressive potential in the presence of
1400 W and BEC may have decreased cellular demand
of intermediates and energy, and so regulated nutrient
uptake to adjust to the lower requirements. The de-
crease of nutrient uptake was not caused by the direct
effects of 1400 W and/or BEC on the expression or ac-
tivity of glucose or glutamine transporters. The presence
of these inhibitors in Jurkat cell cultures did not induce
noticeable effects at the nutritional level (data not
shown), although Jurkat cells and macrophages, as prin-
cipal sub-populations of MSC-1 cells, express the same
nutrient transporters [28,29]. This hypothesis requires
further confirmation using specific siRNA to iNOS and
ARG1 to avoid possible unknown effects associated with
inhibitors that may have caused the down-regulation of
nutrient uptake.
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the TCA cycle with specific intermediates, thus ensuring
its enhanced activity (Figure 3B, C, D). Interestingly,
malate accumulation was initiated around 8 to 16 h be-
fore fumarate and α-KG accumulation. This may appear
illogical since fumarate and α-KG are the upstream
metabolites of malate. The study of metabolic fluxes and
enzymatic kinetics is therefore crucial for understanding
the differences in the trends of metabolite concentra-
tions. The use of labeled nutrients may also offer inter-
esting insight to the origin and fate of each metabolite.
Particularly, the accumulation of fumarate suggests that
L-Arg is continuously synthesized and supports a per-
manent immunosuppressive activity (Figures 1, 3C). Fur-
thermore, the enhanced activity of the TCA cycle
resulted in the accumulation of high levels of malate
compared to PEP (Figures 2D, 3D), both of which are
precursors of pyruvate. This may suggest that the TCA
cycle contributes to lactate accumulation since the lac-
tate production-to-glucose consumption rates reached
values higher than 2 (Figure 2D). BM-derived MDSCs
undergo anaerobic glycolysis despite non-limiting oxy-
gen conditions, a typical behavior for tumor cells that
produce lactate rather than obtaining high energy yields
from respiration. This phenomenon results in the acidifi-
cation of the tumoral microenvironment, a condition
that promotes tumor progression and metastasis [30].
Moreover, the accumulation of fumarate was previously
associated with the inhibition of HIF hydroxylases and
the stable expression of HIF [31]. On that note, our
results agree with recent findings demonstrating that
MDSCs express hypoxia-induction factor-1 α to adapt to
the quasi-hypoxic conditions encountered in tumors
[32]. Similarly, previous work by Wada et al. revealed
that GM-CSF induces a rapid glucose-dependent extra-
cellular acidification that is regulated by protein kinase
C and the sodium/proton antiporter [33]. Moreover,
iNOS activity is associated with an increased glucose
consumption rate, increased glycolysis and PPP, and the
inhibition of oxidative phosphorylation in zymosan-
treated macrophages [34]. Likewise, a study by Irace
et al., on LPS-treated macrophages reported a bi-
directional regulation between NO and TCA cycle, that
supports our findings. NO was shown to regulate aconi-
tase activity and α-ketoglutarate production and altera-
tions of the TCA cycle correlated with the inhibition of
NO biosynthesis [35].
The two principal NADPH producing pathways in
mammalian cells, the TCA cycle and PPP, were also sti-
mulated in the presence of GM-CSF and IL-6. As the
non-oxidative phase of PPP is devoted to anabolic pro-
cesses and BM-derived MDSCs exhibit a low growth rate,
the conversion of G-6-P into F-6-P was probably domin-
ant to the production of 6-phosphogluconolactone, thefirst PPP intermediate. However, NADPH is mostly
derived from the TCA cycle, particularly via malate de-
hydrogenase and isocitrate dehydrogenase, since fluxes
through these pathways were considerably higher than
those through the PPP (Figures 2C, 3B–D), although the
oxidative phase of the latter was shown to be stimulated.
As BM-derived MDSCs exhibited low specific growth
rates in vitro, the oxidative phase, which is responsible
for NADPH production, was probably more active than
the non-oxidative phase, which is related to anabolic pro-
cesses. This resulted in the recycling of PPP intermedi-
ates to the glycolysis pathway.
Although BM-derived MDSCs undergo glycolytic me-
tabolism, with a low energy yield, the specific cell con-
centration of ATP increased gradually during maturation
(Figure 4B). However, the decreasing trend of the ATP-
to-ADP ratio suggests that ATP was continuously
depleted from the intracellular pool (Figure 4E). This
may be due to ATP consumption, forming ADP, or ADP
production from AMP. Nevertheless, the production of
ADP from AMP, via the enzymatic activity of adenylate
kinase, requires ATP. Thus, the decrease of the ATP-to-
ADP ratio was probably caused by ATP consumption.
Enhanced AMPK activity, as suggested by the continu-
ous increase of the AMP-to-ATP ratio (Figure 4D) and
confirmed by p-AMPK blotting (Figure 5A), is most
likely responsible for the up-regulation of ATP-
producing processes. Indeed, AMPK is considered an
energy sensor in several metabolic disorders, such as
cancer and diabetes, where enzymes switch cellular me-
tabolism from anabolic to catabolic in reaction to defi-
cits in cellular energy [36]. IL-6 up-regulated AMPK
activity in rat skeletal muscle cells, and the IL-6-induced
STAT3 enzyme was localized in mitochondria, resulting
in enhanced oxidative phosphorylation and consequently
increased cell ATP levels [37,38]. However, we observed
that BM-derived MDSC respiration decreased in the
presence of GM-CSF and IL-6, probably caused by HIF-
1α expression [32]. The role of AMPK in HIF-1α expres-
sion is cell type dependent. Hypoxia induces HIF-1α
expression in an AMPK-independent manner in mouse
embryonic fibroblasts, whereas enhanced AMPK activ-
ity is important for HIF-1α transcriptional activity
under hypoxic conditions in prostate cancer cell lines
[39]. Therefore, the enhanced activity of AMPK in
BM-derived MDSCs may have had multiple effects, by
switching cells from oxidative phosphorylation to gly-
colysis, supported by Cidad et al., where inhibition of
mitochondrial respiration by NO rapidly stimulated
glucose uptake through AMPK [19]. Alternatively, to
compensate for a deficient energy yield from glycolytic
metabolism, BM-derived MDSCs further stimulated
TCA cycle activity through glutaminolysis to produce
ATP at a higher rate than required by maturation and
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low ATP-to-ADP ratio in the iNOS and 1400 W-
inhibited MSC-1 cell culture indicated that the ATP
consumption rate was higher than that of its net pro-
duction, when compared to the control culture. How-
ever, this low ATP production rate did not stimulate
AMPK in response to the energy deficit as revealed by
the low AMP-to-ATP ratio when compared to the
control culture. This suggests that the enzymatic activ-
ities of iNOS and ARG1 probably regulate AMPK ac-
tivity, and that their inhibition may render AMPK
unresponsive to energy deficit.
To confirm the implications of AMPK in the matur-
ation process of BM cells to MDSCs, we incubated
freshly isolated BM cells with Comp-C, a potent select-
ive and ATP-competitive inhibitor of AMPK [40]. Since
Comp-C is a reversible inhibitor, the expression levels of
p-AMPK were monitored throughout the duration of
culture to confirm the inhibition of AMPK activity
(Figure 5B). The inhibition of AMPK in Comp-C pre-
treated BM cells cultured in the presence of GM-CSF
and IL-6 caused a net decrease in the uptake rate of
major nutrients (glucose and L-Gln). This may have
resulted in the down-regulation of TCA cycle activity
and of the related metabolic pathways, such as L-Arg
endogenous synthesis and energy production. Further-
more, AMPK inhibition down-regulated the GM-CSF
and IL-6–induced activation of iNOS and ARG1
(Figure 5C, D). NADPH, a co-factor of iNOS, is princi-
pally derived from the glutaminolysis/TCA cycle axis
and the decrease of cell specific levels of NADPH caused
the down-regulation of iNOS activity. This finding is
consistent with a previous report where the inhibition of
AMPK activity by Comp-C, or dominant negative
AMPK, down-regulated the activity of PGE2-induced
eNOS (endothelial isoform of NOS), in human epithelial
progenitor cells [20]. Interestingly, GM-CSF and IL-6
failed to activate ARG1 in the AMPK-inhibited BM cells
(Figure 5D), although we recently showed that ARG1 ac-
tivity was not associated with any specific energy
requirements [41]. The activation of the mitogen-
activated protein kinase (MAPK) signaling pathways in-
cluding p38MAPK, ERK1/2 and SAPK/JNK, which are
implicated in BM-derived MDSC maturation [5], was
strictly linked to the induction of iNOS expression in
macrophages [42]. Moreover, the AMPK inhibition-
induced down-regulation of L-Arg endogenous synthesis
and the low affinity of ARG1 for L-Arg (approximately
10 mM) may have contributed to the inactivation of
ARG1. The inhibition of AMPK activity in macrophages
was also shown to inhibit cyclooxygenase-2 activity,
which is crucial for MDSC accumulation in the tumor
microenvironment [43,44]. Therefore, AMPK, via
downstream-activated signaling pathways, is implicatedin the maturation of BM cells to MDSCs. Although the
phenotype of GM-CSF and IL-6-treated AMPK-inhibited
BM cells was not investigated, iNOS and ARG1 activities
were suppressed and led to a non-immunosuppressive
cell population, as revealed by cytotoxicity assay, where
the density and viability of Jurkat cells cultured in the
presence of cytokine-treated Comp-C-pre-treated BM-
cells were similar to those observed in the control culture
(Jurkat cells only) (Figure 5E, F). As for all pharmaco-
logical inhibitors, Comp-C may have off-target effects
that affect the reliability of the results observed here.
Although no Comp-C-related side effects on cell me-
tabolism were reported in the literature, Comp-C could
potentially interact with other cell compartments, pro-
teins or other molecules resulting in experimental bias.
Studying the maturation of BM cells to MDSCs when
the AMPK gene is silenced, using either AMPK knock-
out mice or specific siRNA to AMPK, is thus crucial
before initiating in vivo studies.
Both experimental models suggest that AMPK, iNOS
and ARG1 are co-activated. Several hypotheses can be
suggested to explain the concomitant activation of
iNOS, ARG1 and AMPK and the up-regulation of cen-
tral carbon metabolism. First, all these enzymes and
pathways may have been up-regulated by a direct effect
of GM-CSF and IL-6. Second, the activation of iNOS
and ARG1 may have increased cells demand for energy.
AMPK may have been activated to respond to the en-
ergy deficit since BM-derived MDSCs and MSC-1 cells
exhibit glycolytic metabolism. However, the regulatory
mechanisms between AMPK, iNOS and ARG1 require
further investigation to determine signaling pathways
and signals implicated in this bi-directional regulation.
Conclusions
In conclusion, the present study suggests that alterations
of myelopoiesis, and thus MDSC maturation and the
consequent activation of iNOS and ARG1, may depend
on enhanced central carbon metabolism and up-
regulation of the cell bioenergetic state. Furthermore,
our results for nucleotide-derived behavioral biomarkers,
and on the distribution of TCA cycle intermediates, un-
ambiguously indicate that AMPK is involved in the GM-
CSF and IL-6–induced stimulation of glycolysis and
TCA cycle. Moreover, mature MDSCs, as for its immor-
talized form (MSC-1 cells), undergo anaerobic glycolysis
and partially oxidize L-Gln to ensure favorable condi-
tions for tumor progression, as do cancer cells. These
results may thus have clinical relevance, since the modu-
lation of metabolic fluxes through glycolysis and gluta-
minolysis, via the inhibition of AMPK activity, may
efficiently impair MDSC maturation and their immuno-
suppressive activity and indirectly help to recover anti-
tumoral immune responses.
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Mice
Six- to eight-week-old male C57BL/6 mice were pur-
chased from Charles River (Quebec, Canada) and main-
tained under specific pathogen-free conditions in the
animal facilities of the Université de Montréal. Experi-
ments were performed according to state guidelines and
approved by the Canadian Council on Animal Care.
BM cell culture
Single cell suspensions were prepared from BM of nor-
mal mice and cultured in 100-mm Petri dishes (Becton
Dickinson, Quebec, Canada) in 10 ml of RPMI 1640
medium (Sigma, Ontario, Canada) supplemented with
10% (v/v) irradiated fetal bovine serum (Cedarlane,
Ontario, Canada), 1 mM Sodium Pyruvate (Sigma),
50 μM β-mercaptoethanol (Sigma), 100 U/ml Penicillin,
150 U/ml Streptomycin (Cedarlane) and 2 mM L-
glutamine (Cedarlane), in a 5% CO2 and 37 °C incubator.
MDSCs were derived by treating BM cells with 40 ng/ml
of GM-CSF and 40 ng/ml of IL-6 (both from Cedarlane)
for 4 days as described by Marigo et al. [5].
When required, BM cells were treated for 15 min with
5 μM of Compound C (Comp-C, 6-[4-(2-Piperidin-1-yl-
ethoxy)-phenyl)]-3-pyridin-4-yl-pyrrazolo[1,5-a]-pyrimi-
dine, Sigma) dissolved in DMSO (1% v/v) to inhibit
AMPK activity.
Prior to analysis, cells were detached using a phos-
phate buffer saline (PBS)-EDTA (2 mM) solution, rinsed
with PBS and centrifuged for 6 min at 250 × g at 4 °C.
Cells were counted using a hematocytometer and cell
viability was determined by the Trypan Blue exclusion
method.
MSC-1 cell culture
The generation, culture, and phenotype of the MSC-1
immortalized cell line has been described previously [8].
MSC-1 cells were grown in 75 cm2 T-flasks (VWR, On-
tario, Canada) in RPMI 1640 medium (Sigma) supple-
mented with 10% (v/v) irradiated FBS (Cedarlane), 1 mM
sodium pyruvate (Sigma), 100 U/ml Penicillin, 150 U/ml
streptomycin (Cedarlane) and 2 mM L-glutamine
(Cedarlane), in a 5% CO2 and 37 °C incubator. Cultures
were inoculated at a cell density of 0.2 × 106 cells/ml and
cells were passaged when they reached 80% confluence.
When required, iNOS and ARG1 activities were inhib-
ited with 100 μM of 1400 W and 5 μM of BEC (both
from Cedarlane), respectively.
Prior to analysis, cells were detached using 0.25%
Trypsin and 1 mM EDTA (Invitrogen, Ontario, Canada),
rinsed with PBS and centrifuged for 6 min at 250 × g at
4 °C. Cells were counted using a hemacytometer and
viability was determined using the Trypan Blue exclusion
method.Assays
Glucose, lactate, glutamate and glutamine concentrations
in supernatants were measured using a dual-channel
immobilized oxidase enzyme biochemistry analyzer
(2700 SELECT, YSI Inc. Life Sciences, Yellow Springs,
OH, USA), using calibration buffers provided by the
manufacturer.
Nitric oxide concentrations in supernatant were re-
spectively assayed using a Nitrate/Nitrite Colorimetric
Assay Kit (Cedarlane). Specific rates of nutrients con-
sumption and metabolites production were calculated
using the average method [45].
SDS-PAGE and western blot analyses
Detached cells were lysed in 100 μl of lysis buffer
(50 mM HEPES, pH 7.4, 150 mM NaCl, 1% thesit, and
0.5% sodium deoxycholate), and insoluble material was
removed by centrifugation at 10,000 × g for 5 min at 4°C.
Samples were mixed 3:1 with sample buffer containing
0.6 mM DTT and boiled for 5 min. Proteins were sepa-
rated by 10% SDS-PAGE at 200 V during 45 min. For
Western blots, proteins were transferred to a PVDF
membrane (Bio-Rad, Mississauga, Ontario, Canada)
using Tris-glycine buffer for 1 h at 200 mA. The mem-
brane was blocked with 5% skim milk/10 mM Tris–HCl,
pH7.4, 150 mM NaCl, 0.1% Tween-20 and then probed
with the appropriate primary antibodies (diluted 1:200)
for AMPK α1/2 and p-AMPK α1/2 (Thr172) (Santa
Cruz Biotechnology, Santa Cruz, CA) overnight at 4 °C.
Specific antibody binding was detected using goat anti-
rabbit IgG horseradish peroxidase (diluted 1:1000, R&D
Systems, Minneapolis, MN) for 1 h at room temperature
and visualized using an enhanced chemiluminescence
detection reagent (Bio-Rad). Band intensities were com-
pared with ImageJ software.
Determination of ARG 1 activity
Total cells were lysed with 50 μl of a lysis buffer contain-
ing 0.1% Triton X-100 (Sigma) and 100 μg/ml of pepsta-
tin, antipain and aprotinin (all from EMD BioSciences,
San Diego, CA). After 30 min in a thermomixer at 37 °C,
cell debris was removed by centrifugation at 15,000 × g
for 20 min and cell lysates were kept at −80 °C prior to
analysis. ARG1 activity was quantified in cell lysates by
urea determination with α-isonitrosopropiophenone as
previously described by Munder et al., [46]. One unit of
ARG1 activity is defined as the enzyme activity that cata-
lyzes the production of 1 mol urea/min.
Cytotoxicity assay
The immunosuppressive activity of BM-derived MDSCs
and MSC-1 cells was assessed by their ability to inhibit
Jurkat cell growth (leukemic T-cells, clone E6-1, Cedar-
lane). Experiments were performed in 24-well tissue
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of 1 ml. Jurkat cells were inoculated (500 μl at 0.2 × 106
cells/ml) in MillicellWPC 0.4 μm culture plate inserts
(Millipore) and added to wells containing 500 μl of BM
cell suspension (0.2 × 106 cells/ml) cultured in the pres-
ence of GM-CSF and IL-6 (40 ng/ml each) for 0, 24, 48,
72 and 96 h or to MSC-1 cells cultured in the presence
of 1400 W and BEC (100 and 5 μM, respectively) for
16 h (500 μl at 0.2 × 106cells/ml).
To investigate the role of AMPK in the maintenance
of BM-derived MDSCs immunosuppressive potential,
Comp-C pre-treated BM cells cultured in the presence
of GM-CSF and IL-6 (for 24, 48, 72 and 96 h) were
rinsed with sterile PBS to remove Comp-C and re-
suspended in GM-CSF and IL-6 (40 ng/ml each)
enriched complemented culture medium. Mixed cultures
were kept in a 5% CO2 and 37 °C incubator for 24 h for
BM cells and BM-derived MDSCs, and for 32 h for
MSC-1 cells. Jurkat cells were then counted using a
hemacytometer and viability was determined using the
Trypan Blue exclusion method. The small pore size of
the culture inserts prevented Jurkat cells and detached
BM-derived MDSCs and MSC-1 cells to cross-
contaminate respective media/cell samples and so
ensured the reliability of cell counts.Respirometry test
Respirometry assays were performed as described by
Lamboursain et al., [47]. Briefly, 3 ml of a 15 × 106
BM-derived MDSCs/ml suspension or 3 ml of a 5 × 106
MSC-1 cells/ml suspension were inoculated in a 10-ml
borosilicate glass syringe (Sigma) in which the plunger
was substituted by an Ingold pO2 probe (Mettler To-
ledo, Quebec, Canada). The respirometer was kept at
37 °C and magnetically agitated (60 RPM) to ensure
the homogeneity of cell suspension. Dissolved oxygen
was recorded by an acquisition system (Centris, Long-
ueuil, Canada).Metabolite extraction
The extraction protocol was based on the method devel-
oped by Kimball et al., [48]. Briefly, for each sample,
5 × 106 cells were extracted with 400 μl of 80% cold
methanol in the presence of 0.2 g of sand (Sigma). After
10 min on dry ice, the mixture was vortexed and then
sonicated in ice and water for 5 min. The samples were
then centrifuged for 7 min at 21,000 × g and 4 °C to col-
lect supernatants. The pellets were extracted a second
and third time as described above with 200 μl of 50%
cold methanol and 200 μl of cold water, respectively.
Supernatants were mixed and stored at −80 °C prior to
analysis. Extracts were filtered through 0.2 μm filters
(Millipore, Ontario, Canada) before analysis.Nucleotide concentrations
Nucleotides in BM cell and BM-derived MDSC extracts
were analyzed using a 1290 UPLC system coupled to a
6460 triple quadruple mass spectrometer (both from
Agilent Technologies, Quebec, Canada). Nucleotides were
separated by a Symmetry C18 column (150*2.1 mm,
3.5 μm) (Waters) equipped with a Security C18 guard-
column (Waters, 10*2.1 mm, 3.5 μm) by the ion-pair
method. DMHA (N,N-dimethylhexylanine, Sigma) was
used as an ion-pair reagent to improve the signal-to-
noise ratio with positive ionization mode. The mobile
phase consisted of Buffer A: 10 mM ammonium acetate,
15 mM DMHA at pH 7.0, and Buffer B: 50/50% (v/v)
acetonitrile, 20 mM NH4OAc at pH 7.0. Mobile phase
flow rate was set at 0.3 m/min with the following gradi-
ent: 0–10 min at 10% B, 10–20 min at linear gradient
from 10 to 30% B, 20–21 min at linear gradient from
30 to 60% B, 21–26 min at 60% B, 26–27 min at linear
gradient from 60 to 10% B and 27–35 min at 10% B.
Nucleotide concentrations in MSC-1 cell extracts were
determined by ion-pairing liquid chromatography-
electrospray ionization mass spectrometry (positive
mode) using a HPLC-MS system (Waters, Milford, MA)
equipped with a Symmetry C18 column (150*2.1 mm,
3.5 μm) (Waters) and a Security C18 guard-column
(Waters, 10*2.1 mm, 3.5 μm). Likewise, DMHA was
used as an ion-pair reagent. The mobile phase consisted
of Buffer A, 10 mM ammonium acetate, 15 mM DMHA
at pH 7.0, and Buffer B, 40% (v/v) acetonitrile in water.
The flow rate was set at 0.3 ml/min using the following
gradient: 0–10 min at 15% B, 10–12 min at linear gradi-
ent from 15 to 40% B, 12–30 min at linear gradient from
40 to 70% B, 30–35 min at 70% B, 35–37 min at linear
gradient from 70% to 15% B and 37–45 min at 15% B.
In both cases, quantification of metabolites (nucleotides
and organic acids) was performed by integrating peak
areas and using calibration curves. Cell specific concen-
trations in metabolites were calculated by normalizing
the quantity of metabolites in cell extracts to the num-
ber of extracted cells.
Organic acid concentrations
Organic acids concentrations were assessed using the
above-mentioned UPLC-MS/MS system using a Hyper-
carb column (100*2.1 mm, 5 μm) and a Hypercarb pre-
column (2.1*10, 5 μm) (Thermo Fisher, Ontario,
Canada). The mobile phase consisted of Buffer A,
20 mM ammonium acetate at pH 7.5, and Buffer B,
10% (v/v) methanol in water. The flow rate was set at
0.3 ml/min using the following gradient: 0–5 min at
10% A, 5–10 min at linear gradient from 10% to 20%
A, 10–20 min at linear gradient from 20% to 100% A,
20–30 min at 100% A, 30–32 min at linear gradient
from 100% to 10% A and 32–40 min at 10% A.
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Data are shown as mean± SEM (standard error of
mean) of n= 3 independent experiments from 3 dis-
tinct cell cultures.
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